Cambridge, UK 22 May 2012: Isogenica today announces that it is appointing CTC Laboratory Systems Corporation (CTCLS) of Tokyo, Japan to represent the business in Japan. CTCLS are a leading force in the pharmaceutical research market in Japan and their skilled and knowledgeable employees ensure that Isogenica’s innovative technology for antibody, protein and peptide design will find a new customer base in Japan.
Dr Kevin Matthews, CEO, Isogenica commented: “The appointment of CTCLS is an important milestone for Isogenica and ensures that we can support our key customers in all the major world markets. We understand that direct personal contact, taking account of cultural and language differences, is fundamental to developing strong customer relationships. I am confident that CTCLS is the best organization to represent us and look forward to working with them to introduce Isogenica to the Japanese market as a whole as well as following-up on specific customer opportunities”.
Kevin Matthews, CEO Isogenica - T: +44 (0)1799 533682 - E: firstname.lastname@example.org
Rowan Gardner, Chairman, Biolauncher – T: +44 (0)1799 531635 – E: email@example.com
Rob Scoffin, CEO, Cresset BMD Ltd. – T: +44 (0)1707 356 120 – E: firstname.lastname@example.org